Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Investor Presentation (September 2023)
18 slides from Rockwell Medical's investor presentation, Sep 12, 2023
Slide 1: Investor Presentation September 12, 2023
Investor Presentation September 12, 2023
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell’s expectations regarding revenue, profitability, financial position, 2023 guidan
Slide 3: Rockwell Medical At A Glance
Rockwell Medical At A Glance © 2023 Rockwell Medical, Inc. Business Overview Financial Metrics • Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. • Second largest supplier of acid and bicarbonate co
Slide 4: Executive Management Team
Executive Management Team Mark Strobeck, Ph.D. President and CEO Paul E. McGarry, CPA SVP, Finance and Chief Accounting Officer Megan Timmins EVP, Chief Legal Officer and Secretary © 2023 Rockwell Medical, Inc. Tim T. Chole SVP, Sales and Marketing Heather R. Hunter SVP, Chief Corporate Affairs Offi
Slide 5: Corporate Strategy
© 2023 Rockwell Medical, Inc. Corporate Strategy q Be the Global Leader in Hemodialysis Concentrates q Provide Customers with the Highest Quality and Most Reliable Products and Services q Achieve Profitability and $100M+ Annual Net Sales q Focus on Innovative, Long-Term Growth Opportunities 5
Slide 6: What is Hemodialysis?
What is Hemodialysis? 6 • Procedure whereby a dialysis machine and a special filter called an artificial kidney — or dialyzer — are used to clean a patient’s blood. • Filters out wastes, salts, and excess fluid, and corrects electrolyte and acid-base imbalances for people who have kidney failure, or
Slide 7: U.S. In-Center Hemodialysis Concentrates Market
U.S. In-Center Hemodialysis Concentrates Market Estimated growth driven primarily by increasing number of patients suffering from end-stage kidney disease TODAY 2026 $380M $500M © 2023 Rockwell Medical, Inc. SOURCE: “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022
Slide 8: Indispensable Player in Large, Expanding Market
Indispensable Player in Large, Expanding Market • Rockwell Medical is one of two manufacturers and suppliers that has scalability and transportation infrastructure to service the more than 12,000 individual purchasing facilities (including outpatient dialysis clinics and hospitals) in the U.S., alon
Slide 9: Growth opportunities: market share, complementary products, consolidation
© 2023 Rockwell Medical, Inc. • Rockwell continues to increase its market share in Western U.S. and internationally • Signed Co-Promotion Agreement with B. Braun, targeting customers in the West • Acquired hemodialysis concentrates business from Evoqua Water Technologies • Represents a ~$100M opport
Slide 10: Acquired Hemodialysis Concentrates Business from Evoqua
© 2023 Rockwell Medical, Inc. Background • 20-Year history serving clinics and dialysis patients throughout the U.S. • Legacy brands include Mar Cor, Cantel and Medivators • Well-known throughout the dialysis community Value Add Terms • Profitable, fully automated concentrates business • Generated a
Slide 11: Rockwell Medical Expands Distribution Footprint in the U.S.
Rockwell Medical Expands Distribution Footprint in the U.S. • Acquired Evoqua’s hemodialysis concentrates customer contracts • Added an additional estimated 1,700 clinics in the U.S. • Rockwell Medical now the leading supplier of liquid bicarbonate products in the U.S. 0 1-10 11-50 51-100 101-250 25
Slide 12: Financials and Milestones
Financials and Milestones 12
Slide 13: Delivering on New Business Strategy
Delivering on New Business Strategy Increasing revenue, reducing expenses, driving the Company towards profitability (In Thousands, Except Per Share Amounts) Six Months Ended June 30 2023 2022 Net Sales $ 37,748 $ 34,806 Gross Profit $ 3,632 $ 960 Net Loss $ (5,055) $ (12,128) Adjusted EBITDA* $ (3,
Slide 14: Focused on Driving Business to Profitability in Q4'23
Focused on Driving Business to Profitability in Q4’23 … along with revenue growth, reducing expenses and paying down debt 60 65 70 75 80 85 2021 2022 2023 GUIDANCE ($M) 82.0 – 86.0 72.8 61.9 Net Sales 0 5 10 15 20 YE'21 YE'22 YE'23 YE'24 3/16/25 ($M) 2.0 10.0 Debt* © 2023 Rockwell Medical, Inc.14 -3
Slide 15: Projected Milestones for 2023
Projected Milestones for 2023 15 © 2023 Rockwell Medical, Inc. ü Complete 100% Transfer of Baxter Business with Preferred Economics ü Expand Partnerships with Existing Hemodialysis Customers ü Grow Concentrates Business by Adding New Customers ü Distribute Hemodialysis Products in New Geographies q
Slide 16: Why Invest in Rockwell Medical?
© 2023 Rockwell Medical, Inc. Why Invest in Rockwell Medical? q Revenue-Generating Business q Large and Growing Market Opportunity q Path to Profitability in Q4’23 q Strengthened Financial Position q Attractive Valuation 16
Slide 17: www.rockwellmed.com IR@rockwellmed.com
www.rockwellmed.com IR@rockwellmed.com17
Slide 18: Reconciliation to GAAP Financial Measures
Reconciliation to GAAP Financial Measures To supplement the Company’s financial results presented on a U.S. generally accepted accounting principles (“GAAP”) basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operating metrics. The Company bel
Rockwell Medical — Investor Presentation (September 2023) on 6ix